OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:331244
Who is this for?
Show terms as
3Active trials8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

This entry, listed under Orphanet code 331244, is classified as 'OBSOLETE' — meaning it is no longer an active or recognized disease category in the Orphanet rare disease database. It was previously used as a grouping term for certain immunodeficiency conditions where the main problem was the body's inability to make enough antibodies (also called immunoglobulins). Antibodies are proteins made by the immune system to fight infections caused by bacteria, viruses, and other germs. When the body cannot produce enough of these protective proteins, a person becomes more vulnerable to frequent and sometimes severe infections. Because this classification is obsolete, patients who were once grouped under this term have likely been reclassified into more specific diagnoses. These may include conditions such as common variable immunodeficiency (CVID), selective IgA deficiency, specific antibody deficiency, or other well-defined primary antibody deficiency syndromes. If you or a family member was given this diagnosis, it is important to work with an immunologist or clinical geneticist to determine the current, more precise diagnosis. A more specific diagnosis can guide better treatment decisions, genetic counseling, and access to clinical trials. Treatment for antibody deficiency conditions generally involves immunoglobulin replacement therapy (given through an IV or under the skin), preventive antibiotics, and careful monitoring for infections and related complications.

Key symptoms:

Frequent sinus infectionsRepeated ear infectionsRecurring pneumonia or lung infectionsChronic diarrheaFrequent skin infectionsSlow recovery from common illnessesUnexplained weight loss or poor growth in childrenSwollen lymph nodesFatigue and low energyBronchiectasis (permanent damage to the airways from repeated infections)

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

4 events
Dec 2025Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Octapharma — PHASE3

TrialNOT YET RECRUITING
Dec 2022A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

Grifols Therapeutics LLC — PHASE3

TrialRECRUITING
Nov 2022Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension

Monash University — PHASE2, PHASE3

TrialRECRUITING
Jan 1990Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)

National Institute of Allergy and Infectious Diseases (NIAID)

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 31 trial
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Phase 3
Actively Recruiting
· Sites: St. Petersburg, Florida; Bethesda, Maryland +59 more · Age: 1899 yrs
Other1 trial
Immune Regulation in Patients With Common Variable Immunodeficiency and Related Inborn Errors of Immunity (IEI)
Actively Recruiting
PI: Warren Strober, M.D. (National Institute of Allergy and Infectious Disea) · Sites: Bethesda, Maryland · Age: 2120 yrs

No specialists are currently listed for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defectsForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.

Start the conversation →

Latest news about OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects

No recent news articles for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has my diagnosis been updated to a more specific condition since this category is now obsolete?,What specific type of antibody deficiency do I have, and is genetic testing recommended?,Do I need immunoglobulin replacement therapy, and if so, which method is best for me?,Are there any vaccines I should avoid or that my family members should receive?,How often should I have my immunoglobulin levels and lung function checked?,What signs of complications should I watch for at home?,Are there any clinical trials or new treatments I should know about?

Common questions about OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects

What is OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects?

This entry, listed under Orphanet code 331244, is classified as 'OBSOLETE' — meaning it is no longer an active or recognized disease category in the Orphanet rare disease database. It was previously used as a grouping term for certain immunodeficiency conditions where the main problem was the body's inability to make enough antibodies (also called immunoglobulins). Antibodies are proteins made by the immune system to fight infections caused by bacteria, viruses, and other germs. When the body cannot produce enough of these protective proteins, a person becomes more vulnerable to frequent and s

Are there clinical trials for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects?

Yes — 3 recruiting clinical trials are currently listed for OBSOLETE: Other immunodeficiency syndrome with predominantly antibody defects on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.